Results 31 to 40 of about 305,495 (322)

Prebiotic and Health-Promoting Benefits of Dextran-Type Exopolysaccharide Produced by Leuconostoc mesenteroides SJC113

Foods
The exopolysaccharide (EPS) produced by Leuconostoc mesenteroides SJC113 is a glucan with α-1,6 and α-3,6 branched glycosidic linkages that may promote human health.
Dominika Jurášková, Susana C. Ribeiro, Célia C. G. Silva   +2 more
doaj   +1 more source

ĐIỀU CHẾ NANO VÀNG TRÊN NỀN DEXTRAN VÀ ỨNG DỤNG XÚC TÁC TRONG PHẢN ỨNG KHỬ 4-NITROPHENOL

Tạp chí Khoa học Đại học Huế: Khoa học Tự nhiên, 2019
Trong bài báo này, vật liệu nano vàng (AuNPs) được tổng hợp bằng phương pháp khử hóa học sử dụng dextran với vai trò vừa là chất khử vừa là chất bảo vệ.
Tran Van Quang, Phan Ha Nu Diem, Ton Nu My Phuong, Tran Thai Hoa   +3 more
doaj   +1 more source

The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels [PDF]

, 2013
Aim: Topical administration of siRNA nanocarriers is a promising approach in the treatment of pulmonary disorders. Pulmonary surfactant, covering the entire alveolar surface of mammalian lungs, will be one of the first interfaces that siRNA nanocarriers ...
Braeckmans, Kevin, De Backer, Lynn, De Smedt, Stefaan, Demeester, Jo, Raemdonck, Koen   +4 more
core   +1 more source

Self-diffusion of polymers in cartilage as studied by pulsed field gradient NMR [PDF]

, 2002
Pulsed field gradient (PFG) nuclear magnetic resonance (NMR) was used to investigate the self-diffusion behaviour of polymers in cartilage. Polyethylene glycol and dextran with different molecular weights and in different concentrations were used as ...
Arnold, K., Kärger, J., Naji, L., Schiller, J., Stallmach, F., Trampel, R.   +5 more
core   +2 more sources

Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements [PDF]

, 2009
IT-101, a cyclodextrin polymer-based nanoparticle containing camptothecin, is in clinical development for the treatment of cancer. Multiorgan pharmacokinetics and accumulation in tumor tissue of IT-101 is investigated by using PET.
Alley, B. C. Mack, Braet, C. A. Alabi, C. H. J. Choi, Carter, Cheng, Cheng, Davis, Davis, Dreher, Drummond, Hashizume, Heidel, Hobbs, I. J. Hildebrandt, J. Czernin, J. Hwang, Kirpotin, Loening, M. E. Davis, Matsumura, Moore, O'Connor, Reddy, Riches, Schluep, Schluep, Schluep, T. Schluep, Tabata, Tirona, Torchilin, Yuan   +33 more
core   +3 more sources

Controlled-release kinetics of hydrogen peroxide from dextran-coated calcium peroxide nanoparticles

Materials Research Express
In this study, the controlled release kinetics of hydrogen peroxide (H _2 O _2 ) from dextran-coated calcium peroxide nanoparticles (DEX@CaO _2 (DEX) NPs) were investigated.
N N A Nuar, S N A M Jamil, T S Y Choong, I D M Azmi   +3 more
doaj   +1 more source

Polysaccharide-Based Drug Carriers—A Patent Analysis

Gels
Polysaccharide-based carriers as biomaterials for drug delivery have been inspiring scientists for years due to their exceptional characteristics, such as nontoxicity, biocompatibility, and degradability, as they are able to protect pharmaceutically ...
Snežana Ilić-Stojanović, Fouad Damiri, Adina Magdalena Musuc, Mohammed Berrada   +3 more
doaj   +1 more source

Dextran enzyme imine complexes : a preliminary study : this thesis was presented in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry at Massey University [PDF]

, 1997
A model system involving the formation of protein-dextran complexes has been investigated with a view to improving existing methods of drug administration.
Fisher, Louisa Jane
core  

Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting [PDF]

, 2000
PURPOSE: To prepare polymeric vesicles and niosomes bearing glucose or transferrin ligands for drug targeting. METHODS: A glucose-palmitoyl glycol chitosan (PGC) conjugate was synthesised and glucose-PGC polymeric vesicles prepared by sonication of ...
Couet, W., Dufès, Christine, Gray, A.I., Olivier, J.C., Schätzlein, A.G., Tetley, L., Uchegbu, I.F., Watson, D.G.   +7 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source